Skip to main content Accessibility help
×
Home
Hostname: page-component-768dbb666b-k9l4c Total loading time: 0.338 Render date: 2023-02-06T10:40:05.014Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true

A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy

Published online by Cambridge University Press:  01 January 2021

Abstract

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Columns: Health Policy Portal
Copyright
Copyright © American Society of Law, Medicine and Ethics 2017

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

U.S. Food and Drug Administration News Release, “FDA News Release: FDA Approval Brings First Gene Therapy to the United States,” FDA, August 30, 2017, available at <https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Novartis, “Novartis CAR-T Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation for Treatment of Adult Patients with r/r DLBCL,” April 18, 2017, available at <https://www.novartis.com/news/media-releases/novartis-cart-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation> (last visited Nov. 30, 2017); U.S. Food and Drug Administration, Transcript for the July 12, 2017 Meeting of the Oncologic Drugs Advisory Committee (ODAC) (PM Session), July 12, 2017, at 136-140, available at <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM573721.pdf> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017);+U.S.+Food+and+Drug+Administration,+Transcript+for+the+July+12,+2017+Meeting+of+the+Oncologic+Drugs+Advisory+Committee+(ODAC)+(PM+Session),+July+12,+2017,+at+136-140,+available+at++(last+visited+Nov.+30,+2017).>Google Scholar
Stein, R., “‘Living Drug’ That Fights Cancer By Harnessing Immune System Clears Key Hurdle,” National Public Radio, July 12, 2017, available at <http://www.npr.org/sections/health-shots/2017/07/12/536812206/living-drug-that-fights-cancer-by-harnessing-the-immune-system-clears-key-hurdle> (last visited Nov. 30, 2017); See U.S. Food and Drug Administration, supra note 2, at 137.Google Scholar
See U.S. Food and Drug Administration News Release, supra note 1.Google Scholar
See U.S. Food and Drug Administration News Release, supra note 1.Google Scholar
ClinicalTrials.gov, “Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA),” available at <https://clinicaltrials.gov/ct2/show/NCT02435849> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
U.S. Food and Drug Administration, FDA Briefing Document: Oncologic Drugs Advisory Committee Meeting, BLA 125646:Tisagenlecleucel, Novartis Pharmaceuticals Corporation, at 43, available at <https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM566166.pdf> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
See U.S. Food and Drug Administration, supra note 7, at 16.Google Scholar
Lee, D. W., et al., “Current Concepts in the Diagnosis and Management of Cytokine Release Syndrome,” Blood 124, no. 2 (2014): 188-195, at 191.CrossRefGoogle Scholar
O’Leary, M., U.S. Food & Drug Administration Clinical Presentation: BLA125646, Tisagenlecleucel, Novartis Pharmaceuticals Corporation, July 12, 2017, at 23, available at <https://www.fda.gov/downloads/Advisory-Committees/CommitteesMeetingMaterials/Drugs/OncologicDrugsAdvisoryCommittee/UCM567383.pdf> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
See O’Leary, supra note 10, at 23.Google Scholar
See O’Leary, supra note 10, at 24.Google Scholar
See U.S. Food and Drug Administration, supra note 1.Google Scholar
Lash, A., “After Trial Deaths, Juno Pivots and Scraps Lead CAR-T Therapy,” Exome, March 1, 2017, available at <http://www.xconomy.com/seattle/2017/03/01/after-trial-deaths-juno-pivots-and-scraps-lead-car-t-therapy/#> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Brozak, S., “Gilead-Kite: A New Transformative Deal for Biotech,” Forbes, August 30, 2017, available at <https://www.forbes.com/sites/stephenbrozak/2017/08/30/gilead-kite-a-new-transformative-deal-and-maybe-the-new-future-of-healthcare-deals/#3269e0165d49> (last visited Nov. 30, 2017); Business Wire, “Kite Presents Ongoing Response Rate in Plenary Session from its Pivotal CAR-T Trial of Axicabtagene Ciloleucel in Patients with Aggressive Non-Hodgkin Lymphoma at the 2017 American Association of Cancer Research Annual Meeting,” Business Wire, April 2, 2017, available at <http://www.businesswire.com/news/home/20170402005096/en/Kite-Presents-Ongoing-Response-Rate-Plenary-Session> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017);+Business+Wire,+“Kite+Presents+Ongoing+Response+Rate+in+Plenary+Session+from+its+Pivotal+CAR-T+Trial+of+Axicabtagene+Ciloleucel+in+Patients+with+Aggressive+Non-Hodgkin+Lymphoma+at+the+2017+American+Association+of+Cancer+Research+Annual+Meeting,”+Business+Wire,+April+2,+2017,+available+at++(last+visited+Nov.+30,+2017).>Google Scholar
Novartis Press Release, “Novartis Receives First Ever FDA Approval for a CAR-T Cell Therapy, Kymriah(TM) (CTL019), for Children and Young Adults with B-cell ALL that is Refractory or has Relapsed at Least Twice,” August 30, 2017, available at <https://www.novartis.com/news/media-releases/novartis-receives-first-ever-fda-approval-car-t-cell-therapy-kymriahtm-ctl019> (last visited Nov. 30, 2017); Broderick, J. M., “FDA OKs Tisagenlecleucel in ALL as First Approved CAR T-Cell Therapy,” OncLive, August 30, 2017, available at <http://www.onclive.com/web-exclusives/fda-oks-tisagenlecleucel-in-allas-first-approved-car-tcell-therapy> (last visited No. 30, 2017).+(last+visited+Nov.+30,+2017);+Broderick,+J.+M.,+“FDA+OKs+Tisagenlecleucel+in+ALL+as+First+Approved+CAR+T-Cell+Therapy,”+OncLive,+August+30,+2017,+available+at++(last+visited+No.+30,+2017).>Google Scholar
Grady, D., “F.D.A. Panel Recommends Approval for Gene-Altering Leukemia Treatment,” New York Times, July 12, 2017, available at <https://www.nytimes.com/2017/07/12/health/fda-novartis-leukemia-gene-medicine.html?_r=0> (last visited Nov. 30, 2017); Mukherjee, S., “FDA Panel Backs Groundbreaking Novartis Treatment That Turns Your Cells Into Cancer Killers,” Fortune, July 12, 2017, available at < http://fortune.com/2017/07/12/fda-novartis-car-t-cancer-treatment/> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017);+Mukherjee,+S.,+“FDA+Panel+Backs+Groundbreaking+Novartis+Treatment+That+Turns+Your+Cells+Into+Cancer+Killers,”+Fortune,+July+12,+2017,+available+at+<+http://fortune.com/2017/07/12/fda-novartis-car-t-cancer-treatment/>+(last+visited+Nov.+30,+2017).>Google Scholar
Roland, D. and Loftus, P., “FDA Approves Pioneering Cancer Treatment With $475,000 Price Tag,” Wall Street Journal, August 30, 2017, available at <https://www.wsj.com/articles/fda-approves-first-gene-therapy-in-us-1504108512> (last visited September 7, 2017).+(last+visited+September+7,+2017).>Google Scholar
Patients for Affordable Drugs Press Release, “Statement From Patients For Affordable Drugs On Novartis’ Drug Price,” Patients For Affordable Drugs, August 30, 2017, available at <http://www.patientsforaffordable-drugs.org/2017/08/30/statement-from-patients-for-affordable-drugs-on-novartis-drug-price/> (last visited Nov. 30, 2017); Weintraub, A., “Novartis CEO Opens Door to Cancer Patient Demanding ‘Fair’ CAR-T Pricing,” FiercePharma, August 21, 2017, available at <http://www.fiercepharma.com/financials/patient-advocacy-group-demands-fair-car-t-pricing-from-novartis> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017);+Weintraub,+A.,+“Novartis+CEO+Opens+Door+to+Cancer+Patient+Demanding+‘Fair’+CAR-T+Pricing,”+FiercePharma,+August+21,+2017,+available+at++(last+visited+Nov.+30,+2017).>Google Scholar
See Novartis Press Release, supra note 16.Google Scholar
See Novartis Press Release, supra note 16.Google Scholar
Kaltenboeck, A. and Bach, P. B., “Outcomes-Based Drug Contracts Do Not Move Us Closer to Value,” Morning Consult, June 21, 2017, available at <https://morningconsult.com/opinions/outcomes-based-drug-contracts-not-move-us-closer-value/> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Berkrot, B., “Novartis Gene Therapy Approval Signals New Cancer Treatment Era,” Reuters, August 30, 2017, available at <https://www.reuters.com/article/us-novartis-fda/novartis-gene-therapy-approval-signals-new-cancer-treatment-era-idUSKCN1BA-1ZY> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Novartis Press Release, “Novartis CAR-T Cell Therapy CTL019 Receives FDA Breakthrough Therapy Designation for Treatment of Adult Patients with r/r DLBCL,” Novartis, April 18, 2017, available at <https://www.novartis.com/news/media-releases/novartis-car-t-cell-therapy-ctl019-receives-fda-breakthrough-therapy-designation> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Experts in Chronic Myeloid Leukemia, “The Price of Drugs for Chronic Myeloid Leukemia (CML) is a Reflection of the Unsustainable Prices of Cancer Drugs: From the Perspective of a Larger Group of CML Experts,” Blood 121, no. 22 (2013): 4439-4442, at 4440; Pazdur, R., Letter to Robert A. Miranda, Associate Director Drug Regulatory Affairs at Novartis Pharmaceuticals Corporation, 2001, available at <https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/21335s001ltr.pdf> (last visited Nov. 30, 2017).Google Scholar
Tversky, A. and Kahneman, D., “Judgement under Uncertainty: Heuristics and Biases,” Science 185, no. 4157 (1974): 1124-1131, at 1129.CrossRefGoogle Scholar
21 U.S.C. § 360ff (2016).Google Scholar
Gaffney, A., RAC, Mezher, M., Brennan, Z., “Regulatory Explainer: Everything You Need to Know About FDA’s Priority Review Vouchers,” Regulatory Affairs Professionals Society, August 30, 2017, available at <http://www.raps.org/Regulatory-Focus/News/2015/07/02/21722/Regulatory-Explainer-Everything-You-Need-to-Know-About-FDA%E2%80%99s-Priority-Review-Vouchers/> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
National Cancer Institute, NCI Guidelines For Investigators: Adverse Event Reporting Requirements For DCTD (CTEP and CIP) and DCP INDs A IDEs, March 28, 2011, at 22-23, available at <https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/aeguidelines3-29-11.pdf> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Bryan, W. W., “Letter to Dr. Patel on STN: BL 125646/0,” August 30, 2017, available at <https://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM574106.pdf> (last visited Nov. 30, 2017).+(last+visited+Nov.+30,+2017).>Google Scholar
Brennan, Z., “‘Historic Action’: FDA Approves First CAR-T Therapy,” Regulatory Affairs Professionals Society, August 30, 2017, available at <http://raps.org/Regulatory-Focus/News/2017/08/30/28367/Historic-Action-FDA-Approves-First-CAR-T-Therapy/> (last visited Nov. 30, 2017)+(last+visited+Nov.+30,+2017)>Google Scholar
X. Lin, Statistical Review, Biologics License Application 125646/0, U.S. Food and Drug Administration, at 24, available at <https://www.fda.gov/BiologicsBloodVaccines/CellularGene-TherapyProducts/ApprovedProducts/ucm573706.htm>; see ClinicalTrials.gov, supra note 5.;+see+ClinicalTrials.gov,+supra+note+5.>Google Scholar
See U.S. Food and Drug Administration, supra note 7, at 40; see Clinical-Trials.gov, supra note 6.Google Scholar
7
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *